Adults (18 or more than 18 years old) with Diabetic ketoacidosis basal insulin diabetic ketoacidosis hypoglycemia hypokalemia long-acting insulin rebound hyperglycemia type 2 diabetes mellitus
Conditions
Interventions
Insulin degludec 0.3 unit/kg (adjusted dose to 0.15 u/kg in patients with CrCl less than 30 ml/min)
add on standard treatment of DKA (ADA guideline 2009),Standard treatment of DKA (ADA guideline 2009
Experimental Drug,No Intervention No treatment
Degludec,Standard treatment of DKA
Sponsors
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand (Funding for project number RF66046).
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Adult patients who age at least 18 years old and were diagnosed with DKA
Exclusion criteria
Exclusion criteria: Insulin allergy Euglycemic DKA (Plasma glucose levels lower than 250 mg/dL,) Hemodynamic instability (need vasopressor to maintain hemodynamic status) Pregnant or breastfeeding women Receive a SC treatment regimen for mild DKA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to resolution of DKA When meet the complete criteria of DKA resolution Time to resolution of DKA in medical record | — |
Secondary
| Measure | Time frame |
|---|---|
| Rebound hyperglycemia at least 12 hours after discontinuation of IV insulin infusion Routinely checked capillary blood glucose (at least 4 times per day: before meal and bedtime) after discontinuation of IV insulin infusion,Hypoglycemia During receive intravenous insulin infusion and 24 hours after DKA resolution Capillary blood glucose below than 70 mg/dL,Hypokalemia During receive intravenous insulin infusion and 24 hours after DKA resolution Serum potassium below than 3.5 mEq/L | — |
Countries
Thailand
Contacts
Public ContactKitti Thammakosol
Faculty of Medicine Ramathibodi hospital
Outcome results
None listed